Cargando…

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors

Tyrosine kinase inhibitors (TKI) are the mainstay treatment of BCR-ABL1-positive leukemia and virtually all patients with chronic myeloid leukemia in chronic phase (CP CML) respond to TKI therapy. However, there is limited information on the cellular mechanisms of response and particularly on the ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietarinen, Paavo O., Eide, Christopher A., Ayuda-Durán, Pilar, Potdar, Swapnil, Kuusanmäki, Heikki, Andersson, Emma I., Mpindi, John P., Pemovska, Tea, Kontro, Mika, Heckman, Caroline A., Kallioniemi, Olli, Wennerberg, Krister, Hjorth-Hansen, Henrik, Druker, Brian J., Enserink, Jorrit M., Tyner, Jeffrey W., Mustjoki, Satu, Porkka, Kimmo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410248/ https://www.ncbi.nlm.nih.gov/pubmed/28186983 http://dx.doi.org/10.18632/oncotarget.15146

Ejemplares similares

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
por: Pietarinen, P O, et al.
Publicado: (2015)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
por: El Missiry, Mohamed, et al.
Publicado: (2017)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Standardized assays to monitor drug sensitivity in hematologic cancers
por: Ayuda-Durán, Pilar, et al.
Publicado: (2023)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
por: Kuusanmäki, Heikki, et al.
Publicado: (2017)

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
por: Kreutzman, Anna, et al.
Publicado: (2014)

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
por: Hohtari, Helena, et al.
Publicado: (2019)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate
por: Chou, C. James, et al.
Publicado: (2008)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy
por: Ilander, Mette, et al.
Publicado: (2014)

Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs
por: Khan, Suleiman A, et al.
Publicado: (2012)

Identification of novel regulators of STAT3 activity
por: Parri, Elina, et al.
Publicado: (2020)

screenwerk: a modular tool for the design and analysis of drug combination screens
por: Hanes, Robert, et al.
Publicado: (2022)

Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening
por: Grad, Iwona, et al.
Publicado: (2021)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

From drug response profiling to target addiction scoring in cancer cell models
por: Yadav, Bhagwan, et al.
Publicado: (2015)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Sumo and the cellular stress response
por: Enserink, Jorrit M.
Publicado: (2015)

Chemical Genetics: Budding Yeast as a Platform for Drug Discovery and Mapping of Genetic Pathways
por: Enserink, Jorrit M.
Publicado: (2012)

Metabolic pathways further increase the complexity of cell size control in budding yeast
por: Enserink, Jorrit M.
Publicado: (2014)

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)

Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation
por: Andersson, E I, et al.
Publicado: (2013)

Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
por: Majumder, Muntasir Mamun, et al.
Publicado: (2017)

Identification of structural features in chemicals associated with cancer drug response: a systematic data-driven analysis
por: Khan, Suleiman A., et al.
Publicado: (2014)

Functional characterization of two rare BCR–FGFR1(+) leukemias
por: Barnes, Evan J., et al.
Publicado: (2020)

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia
por: Zabriskie, M S, et al.
Publicado: (2016)

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
por: Kreutzman, Anna, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ggpkjunf88ne93h257582h5kb6